Cell Therapeutics Management Discusses Q4 2012 Results – Earnings Call …Seeking AlphaAs you may recall, this is a randomized trial of pixantrone-rituximab versus gemcitabine-rituximab in patients with aggressive B-cell NHL relapse after receiving CHO…
Monoclonal Antibodies Market – Global Industry Size, Share, Trends, Analysis …SBWire (press release)Albany, NY — (SBWIRE) — 02/28/2013 — Monoclonal antibodies have brought a paradigm shift in biotechnology and pharmaceutical sectors. Monoclonal an…
Antibody response linked with rejection in pediatric kidney transplant recipientsEurekAlert (press release)Pediatric kidney transplant recipients who have antibodies directed against their new organ are more likely to experience kidney injury and rejec…
 Medgadget.com |
Rod Shaped Chemotherapy Drugs Coated With Antibodies Aggressively Attack …
Medgadget.com Chemotherapy medications can be finicky when attacking cancers, showing efficacy but often not enough to subdue the disease. A team of researchers from UC Santa Barbara, South Korea’s Pusan National University, and Genentech decided to investigate … From Spheres To Rods, Reshaping Chemotherapy Drugs May Make Them Far …RedOrbit Nanorods 10000x better at targeting cancerFuturity: Research News |
Research and Markets: Monoclonal Antibodies Market in Rheumatoid Arthritis to …Fort Mills TimesThe currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting fo…
Research and Markets: Monoclonal Antibodies Market in Rheumatoid Arthritis to …Business Wire (press release)The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, co…
|
In a broken health system, greed is winning
Greensboro News & Record Recchi was charged $13,702 for “1 RITUXIMAB INJ 660 MG.” That’s an injection of 660 mg of a cancer wonder drug called Rituxan. The average price paid by all hospitals for this dose is about $4,000, but MD Anderson probably gets a volume discount that … |
|
Novel Chemotherapies More Often Used On- Than Off-Label
Monthly Prescribing Reference … maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole.” One author disclosed financial ties to Genentech; a second author is an economic expert for plaintiffs in suit against the … |
|
Global orphan drugs market led by Roche’s rituximab
The Pharma Letter The prize for the top selling drug went to rituximab, an oncology treatment sold by Swiss drug major Roche (ROG: SIX) which sell it under the trade name Rituxan. This drug has present day peak sales value of $7 billion and a discounted peak value of … |
Monoclonal Antibodies Market Analysis and Forecasts to 2018 in New Research …DigitalJournal.com (press release)The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expires in the forecast p…